Abstract
Using a panel of monoclonal antibodies which detect framework determinants of human-Ia alpha and beta polypeptides and the DC-specific monoclonal antibody Genox 353, the in vitro effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) on the expression of Ia antigens by cells from chronic lymphocytic leukemia (CLL) patients have been studied. In all subjects studied a great increase in expression of framework Ia determinants was found following culture of CLL cells for 90 h with TPA at 10(-7) g/ml. TPA treatment of CLL cells also induced increased expression of Genox 353+ antigens, in some cases where Genox 353 binding was either negligible or not detectable in cells cultured in the absence of TPA.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.